Translating Antigen-Specific Immune Tolerance Approaches to Mitigate Immunogenicity of Biologic Therapies
Time: 2:35 pm
day: Pre-Conference Workshop Day
Details:
Dive into harnessing antigen-specific immune tolerance strategies and expertise to inhibit unwanted immune responses against protein and enzyme therapies, AAV gene therapies, and more. Capitalize on your antigen-specific autoimmune tolerance approaches and capture this opportunity at your fingertips.
- Understanding which cell populations become tolerized in drug-specific tolerance approaches Discussing pros and cons of applying antigen-specific immune tolerance technologies to anti-drug antibody responses vs treatment of autoimmune diseases
- Highlighting how anti-drug antibodies can compromise the safety and efficacy of biological drugs
- Identifying product opportunities for mitigating anti-drug antibody responses
- Delving into a case study of translating an antigen-specific immune tolerance technology from a preclinical idea to a successful end of Phase III
- Exploring the opportunity in gene therapy and how mitigation of immunogenicity can transform the field
- Evaluating potential combination therapy approaches to tackle the most difficult immunogenic proteins
